270 related articles for article (PubMed ID: 29218872)
1. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies.
Xu J; Regan-Fendt K; Deng S; Carson WE; Payne PRO; Li F
Pac Symp Biocomput; 2018; 23():92-103. PubMed ID: 29218872
[TBL] [Abstract][Full Text] [Related]
2. Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.
Regan-Fendt KE; Xu J; DiVincenzo M; Duggan MC; Shakya R; Na R; Carson WE; Payne PRO; Li F
NPJ Syst Biol Appl; 2019; 5():6. PubMed ID: 30820351
[TBL] [Abstract][Full Text] [Related]
3. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles.
Li X; Xu Y; Cui H; Huang T; Wang D; Lian B; Li W; Qin G; Chen L; Xie L
Artif Intell Med; 2017 Nov; 83():35-43. PubMed ID: 28583437
[TBL] [Abstract][Full Text] [Related]
4. DrugComboRanker: drug combination discovery based on target network analysis.
Huang L; Li F; Sheng J; Xia X; Ma J; Zhan M; Wong ST
Bioinformatics; 2014 Jun; 30(12):i228-36. PubMed ID: 24931988
[TBL] [Abstract][Full Text] [Related]
5. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
[TBL] [Abstract][Full Text] [Related]
6. MD-Miner: a network-based approach for personalized drug repositioning.
Wu H; Miller E; Wijegunawardana D; Regan K; Payne PRO; Li F
BMC Syst Biol; 2017 Oct; 11(Suppl 5):86. PubMed ID: 28984195
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Drug Combination Prediction by Integrating Multiomics Data in Deep Learning Models.
Zhang T; Zhang L; Payne PRO; Li F
Methods Mol Biol; 2021; 2194():223-238. PubMed ID: 32926369
[TBL] [Abstract][Full Text] [Related]
8. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
9. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.
Chapman PB; Solit DB; Rosen N
Cancer Cell; 2014 Nov; 26(5):603-4. PubMed ID: 25517746
[TBL] [Abstract][Full Text] [Related]
10. An integrated framework for identification of effective and synergistic anti-cancer drug combinations.
Sharma A; Rani R
J Bioinform Comput Biol; 2018 Oct; 16(5):1850017. PubMed ID: 30304987
[TBL] [Abstract][Full Text] [Related]
11. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
12. BRAF inhibitors in cancer therapy.
Hertzman Johansson C; Egyhazi Brage S
Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
[TBL] [Abstract][Full Text] [Related]
13. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
14. A Computational Approach for Identifying Synergistic Drug Combinations.
Gayvert KM; Aly O; Platt J; Bosenberg MW; Stern DF; Elemento O
PLoS Comput Biol; 2017 Jan; 13(1):e1005308. PubMed ID: 28085880
[TBL] [Abstract][Full Text] [Related]
15. Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction.
Huang L; Brunell D; Stephan C; Mancuso J; Yu X; He B; Thompson TC; Zinner R; Kim J; Davies P; Wong STC
Bioinformatics; 2019 Oct; 35(19):3709-3717. PubMed ID: 30768150
[TBL] [Abstract][Full Text] [Related]
16. Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.
Oddo D; Sennott EM; Barault L; Valtorta E; Arena S; Cassingena A; Filiciotto G; Marzolla G; Elez E; van Geel RM; Bartolini A; Crisafulli G; Boscaro V; Godfrey JT; Buscarino M; Cancelliere C; Linnebacher M; Corti G; Truini M; Siravegna G; Grasselli J; Gallicchio M; Bernards R; Schellens JH; Tabernero J; Engelman JA; Sartore-Bianchi A; Bardelli A; Siena S; Corcoran RB; Di Nicolantonio F
Cancer Res; 2016 Aug; 76(15):4504-15. PubMed ID: 27312529
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of melanoma using kinase inhibitors.
Heppt MV; Tietze JK; Graf SA; Berking C
Curr Opin Oncol; 2015 Mar; 27(2):134-40. PubMed ID: 25602684
[TBL] [Abstract][Full Text] [Related]
18. Profiling networks of distinct immune-cells in tumors.
Clancy T; Hovig E
BMC Bioinformatics; 2016 Jul; 17(1):263. PubMed ID: 27377892
[TBL] [Abstract][Full Text] [Related]
19. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
[TBL] [Abstract][Full Text] [Related]
20. Targeting BRAF in melanoma: biological and clinical challenges.
MandalĂ M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]